- Home
- SCSC vs SPRY Comparison
SCSC vs SPRY Comparison
Compare SCSC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCSC | SPRY |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.2M | 823.2M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SCSC | SPRY |
|---|---|---|
| Price | $42.28 | $8.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $43.00 | $40.00 |
| AVG Volume (30 Days) | 209.6K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $3,846,260,000.00 | $84,278,000.00 |
| Revenue This Year | $2.60 | $87.40 |
| Revenue Next Year | $4.01 | $81.64 |
| P/E Ratio | $17.97 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $33.76 | $6.66 |
| 52 Week High | $46.64 | $18.63 |
Technical Indicators
Market Signals| Indicator | SCSC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 44.49 |
| Support Level | $38.98 | $8.05 |
| Resistance Level | $42.93 | $8.61 |
| Average True Range (ATR) | 1.75 | 0.48 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 34.90 | 25.52 |
Price Performance
Historical ComparisonAbout SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.